Sensei Biotherapeutics schedules June 10 vote on Series B conversion that would trigger change of control

Sensei Biotherapeutics, Inc.

Annual meeting on June 10, 2026 to vote on conversion of Series B Preferred Stock into common stock.
Conversion would issue ~24.4M shares, representing >20% of outstanding and result in change of control per Nasdaq rules.
Pro forma shows reclassification of $321.9M from preferred stock to equity; net loss per share improves from $131.45 to $6.62.
Conversion contingent on stockholder approval; if approved, occurs three business days after vote.

item 8.01 item 9.01

Featured in Daily 8-K Digest

Selected #7 for 2026-05-21. Read digest

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-234882
form_type: 8-K
ticker: SNSE
cik: 0001829802
company_name: Sensei Biotherapeutics, Inc.
filed_at: 2026-05-21T21:12:40+00:00
discovered_at: 2026-05-21T21:14:00.337248+00:00
generated_at: 2026-05-21T21:16:41.357067+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-234882
json_url: https://secwatch.observer/filing/0001193125-26-234882.json
markdown_url: https://secwatch.observer/filing/0001193125-26-234882.md
text_url: https://secwatch.observer/filing/0001193125-26-234882.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526234882/0001193125-26-234882-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526234882/d162035d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-234882

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.